Get the Stockscreener App
15.77
0.67%
0.1133
Kalvista Pharmaceuticals Inc stock is traded at $15.77, with a volume of 749.89K.
It is up +0.67% in the last 24 hours and down -4.05% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$15.66
Open:
$15.962
24h Volume:
749.89K
Relative Volume:
0.59
Market Cap:
$796.86M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-4.2746
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
+0.54%
1M Performance:
-4.05%
6M Performance:
+31.59%
1Y Performance:
+81.62%
1-Day Range:
$15.19
$16.17
1-Week Range:
$15.12
$16.45
52-Week Range:
$7.30
$17.30
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
15.77 | 791.55M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $32.00 - MarketBeat
Needham raises Kalvista Pharmaceuticals stock price target on Ekterly launch success - Investing.com
KalVista Pharmaceuticals (KALV): Needham Raises Price Target to $32 | KALV Stock News - GuruFocus
Millennium Management LLC Acquires Additional Shares in KalVista Pharmaceuticals - GuruFocus
KalVista Pharmaceuticals Inc 4XC1 Stock Analysis and ForecastTrading Volume Trends & No Fee. No Catch. Just Smart Investment Ideas - earlytimes.in
2025 Drug Launches Underscore Commercial Headwinds For New Products - Citeline News & Insights
How KalVista Pharmaceuticals Inc. (4XC1) stock moves in volatile trading sessionsPrice-to-Book Ratio Updates & Buy Sell Timing Alerts - bollywoodhelpline.com
Precision Trading with Kalvista Pharmaceuticals Inc. (KALV) Risk Zones - Stock Traders Daily
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 5.1% HigherShould You Buy? - MarketBeat
KalVista Pharmaceuticals, Inc.Common Stock (NQ: KALV - FinancialContent
KalVista Pharmaceuticals (KALV) Gains Approval for EKTERLY in Ja - GuruFocus
Japan approves KalVista’s oral HAE treatment Ekterly By Investing.com - Investing.com Canada
KalVista (KALV) Gains Approval for Ekterly in Japan - GuruFocus
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (KALV) Movement - Stock Traders Daily
Will KalVista Pharmaceuticals Inc. stock attract ESG investors2025 Sector Review & Smart Money Movement Tracker - Улправда
KalVista Pharmaceuticals Earnings Notes - Trefis
KalVista Shares Navigate Post-Rally Consolidation Phase - AD HOC NEWS
Sentiment Review: How KalVista Pharmaceuticals Inc. (4XC1) stock expands through international marketsTrade Risk Assessment & Stepwise Swing Trade Plans - Улправда
Why KalVista Pharmaceuticals Inc. stock is favored by pension funds2025 Bull vs Bear & Free Community Consensus Stock Picks - DonanımHaber
Can KalVista Pharmaceuticals Inc. stock outperform in 2025 bull marketJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - DonanımHaber
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV) and Novan (NOVN) - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year HighHere's Why - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $898,000 Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Stempoint Capital LP Cuts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Discipline and Rules-Based Execution in KALV Response - news.stocktradersdaily.com
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $120,423.94 in Stock - MarketBeat
Possible Bearish Signals With KalVista Pharmaceuticals Insiders Disposing Stock - simplywall.st
Pharvaris surges, pulling KalVista out of a slump, on promising new HAE treatment - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Receives Buy Rating from Needham & Company LLC - MarketBeat
KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Stonepine Capital Management LLC - MarketBeat
Saturn V Capital Management LP Sells 192,267 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Schroder Investment Management Group Has $6.27 Million Stock Holdings in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals Executive Sells Shares to Cover Tax Obligations - TradingView
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 15%Here's What Happened - MarketBeat
Panagora Asset Management Inc. Grows Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (KALV) Rating Reiterated by Needham | K - GuruFocus
KalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on Thursday - MarketBeat
Pharvaris’s Phase III HAE Data Position Deucrictibant For 2026 NDA Filing - Citeline News & Insights
Kalvista stock price target maintained at $30 by TD Cowen amid competitor data - Investing.com Nigeria
Biotechs Duke It Out In A Genetic Disease — And Both Surge - Investor's Business Daily
Pharvaris’ oral deucrictibant hits endpoints in acute HAE trial - BioWorld MedTech
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
Why pension funds invest in KalVista Pharmaceuticals Inc. (4XC1) stockWeekly Profit Analysis & High Conviction Buy Zone Alerts - Newser
Will KalVista Pharmaceuticals Inc. (4XC1) stock profit from automation waveJuly 2025 Review & Safe Capital Investment Plans - Newser
KalVista Pharmaceuticals (KALV) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How KalVista Pharmaceuticals Inc. stock reacts to inflationary pressures2025 EndofYear Setup & Free High Return Stock Watch Alerts - Newser
Is KalVista Pharmaceuticals Inc. stock a contrarian buyJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kalvista Pharmaceuticals Inc Stock (KALV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sweeny Nicole | Chief Commercial Officer |
Nov 24 '25 |
Sale |
13.45 |
3,813 |
51,289 |
39,728 |
| Piekos Brian | Chief Financial Officer |
Nov 24 '25 |
Sale |
13.45 |
4,471 |
60,139 |
10,529 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 24 '25 |
Sale |
13.45 |
4,331 |
58,256 |
223,508 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Nov 24 '25 |
Sale |
13.45 |
5,296 |
71,236 |
131,831 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 24 '25 |
Sale |
13.45 |
10,940 |
147,154 |
416,189 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 20 '25 |
Option Exercise |
0.00 |
87,390 |
376 |
220,964 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 18 '25 |
Sale |
14.48 |
4,466 |
64,665 |
403,879 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 18 '25 |
Sale |
14.48 |
2,683 |
38,848 |
133,574 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Nov 18 '25 |
Sale |
14.48 |
3,075 |
44,524 |
125,877 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 12 '25 |
Sale |
11.55 |
3,328 |
38,438 |
398,981 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):